SPEEDX
18.3.2021 08:02:09 CET | Business Wire | Press release
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx Resistance Plus® and Plex PCR® tests. Neogen Diagnostik Sağlık Hizmetleri Ltd Şti will distribute all SpeeDx tests throughout Turkey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005254/en/
“We continue to see demand for our key tests and technology around the world,” says Warwick Need, SpeeDx Director of Sales. “Neogen Diagnostik are a great fit for SpeeDx products and we are looking forward to working with them to give Turkish laboratories the opportunity to provide ResistancePlus tests and support the use of Resistance Guided Therapy with their clinician partners.”
In addition to Resistance Plus GC* - combining Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility, and Resistance Plus MG* - simultaneously detecting Mycoplasma genitalium and genetic markers for azithromycin resistance, the SpeeDx sexual health portfolio includes Plex PCR VHS* - a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis), and Plex PCR HSV-1&2, VZV.
SpeeDx are also growing their Respiratory portfolio with the recently launched Plex PCR RespiVirus - a comprehensive multiplex panel for respiratory virus testing, and the soon to be launched Plex PCR SARS-CoV-2 test – a dual target COVID-19 assay for confident detection of all currently known circulating variants. A respiratory bacterial infection testing solution will also be launched this year.
“Neogen Diagnostik is pleased to make Resistance Guided Therapy available to all stakeholders in the Turkey healthcare chain from clinicians and lab specialists to patients through this distributorship deal with SpeeDx. This is absolutely of medical value complementing the rational use of antibiotics when treating patients. SpeeDx solutions will be a real diagnostic tool for clinicians when deciding on the best possible treatment options for their patients,” Abdulmecit Arikan, founder of Neogen Diagnostik, said in a statement.
*available where CE-mark is accepted, not available in the U.S.
About SpeeDx Pty Ltd
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. SpeeDx Resistance Plus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com
About Neogen Diagnostik Sağlık Hizmetleri Ltd Şti
Neogen Diagnostik is a medical company founded by Abdulmecit Arikan, a Molecular Biologist with 18 years of experience in executive positions at a leading multinational diagnostics company and 20+ years corporate experience. Neogen Diagnostik is committed to providing access to advanced technologies used for diagnostic purposes in healthcare, believing that innovative technologies with value-based solutions can eliminate the existing obstacles in molecular diagnostics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005254/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ZincFive Expands Nickel-Zinc Technology into In-Rack Backup and AI Dynamic Power Solutions28.9.2026 14:05:00 CEST | Press release
Applying proven high-rate nickel-zinc technology to in-rack backup and AI-driven transient power applications ZincFive®, the leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced its expansion into in-rack energy storage with the development of Battery Backup Unit (BBU) and AI Dynamic Power Module (DPM) solutions designed to address the evolving energy storage requirements of AI data centers. As AI drives higher rack power densities and increasingly dynamic workloads, data center power architectures are evolving to manage both traditional backup requirements and rapid, repeated changes in power demand. These transient loads can place significant stress on electrical infrastructure, creating a growing need for power solutions closer to the rack that can respond quickly, safely, and reliably. Today’s rack-level technologies often require tradeoffs between energy capacity and dynamic power response. Traditional BBUs are primarily designed t
Oscilloquartz and Iridium expand resilient positioning and navigation capabilities with new PNT service integration28.9.2026 14:00:00 CEST | Press release
News summary: Defense and critical infrastructure require resilient PNT architectures that maintain trusted timing and positioning during GNSS loss Oscilloquartz is expanding Iridium® PNT (formerly Iridium STL®) support across its portfolio, enabling customers to leverage resilient positioning and navigation alongside trusted timing across more applications Collaboration strengthens multi-layered assured PNT architectures by combining Oscilloquartz’s timing portfolio with Iridium satellite services Oscilloquartz today announced the next phase of its collaboration with Iridium Communications Inc., expanding the range of Iridium® positioning, navigation and timing (PNT) (formerly Iridium Satellite Time and Location® or STL®) capabilities available across its synchronization portfolio. The latest integration brings resilient positioning and navigation alongside trusted timing to a broader range of applications. Building on the companies’ existing collaboration, it strengthens end-to-end,
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus28.9.2026 14:00:00 CEST | Press release
– Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24– 48-week data from Phase 2b portion of AZURE-1 demonstrate deepening viral suppression and increased rates of ALT normalization with longer-term treatment– Favorable safety and tolerability profiles observed; no new safety signals– Mirum to host conference call to discuss topline results today, September 28, at 8:30 a.m. ET Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV). In addition, 48-week data from the Phase 2b portion of AZURE-1 demonstrated deepening viral suppression, with a greater proportion of patients achieving HDV RNA below the lower limit of quantification (LLOQ, <10 IU/mL)
Mirion Technologies to Host Inaugural Mirion Connect EMEA/APAC Conference in Brussels28.9.2026 14:00:00 CEST | Press release
Mirion Connect 2026 EMEA/APAC is Mirion Technologies’ first regional nuclear and radiation safety technology conference for Europe, the Middle East, Africa and Asia-Pacific.The conference expands the US-based Mirion Connect event, bringing together experts and technology users across nuclear safety, measurement technologies and radiation science for training, industry forums, product demonstrations and more.Featured speakers will cover topics like radiopharmaceutical advancements, nuclear energy expansion, global environmental testing and capacity-building, and growth in small modular reactor technology Mirion Technologies, a leading provider of advanced radiation safety solutions, today announced Mirion Connect 2026 EMEA/APAC, the company’s first regional edition of its Mirion Connect conference for Europe, the Middle East, Africa and Asia-Pacific region. The event will take place September 29 – October 1, 2026, in Brussels, Belgium. Mirion Connect, an event hosted in the United State
Xceedance Reports 35-50% Efficiency Gains in Insurance Operations Through AI Orchestration28.9.2026 14:00:00 CEST | Press release
Production deployments on Xceedance’s agent studio have delivered approximately 35% efficiency improvements at go-live, with some early implementations approaching 50% through ongoing optimization and operational learning. Xceedance said today that AI orchestration is producing measurable efficiency gains in live insurance operations, delivered through Orchestrated Intelligence, its operating model, and IAN, its agent studio for insurance. In agency and broker operations, processes moved onto IAN delivered around 35% efficiency improvement from the point of go-live. As these implementations have matured, some are now approaching 50%. Xceedance is seeing the same pattern in underwriting support for excess and surplus lines carriers. The company is also deploying AI at scale in claims third-party administration (TPA) operations, where the volume of repeatable work is large. A significant portion of gains comes from Xceedance teammates continuously refining AI-enabled workflows — correcti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom